ASHG 2025
Event details
Date
Location
Boston M.A, United States
Discover the Future of Proteomics at ASHG 2025
Join Olink at Booth #747 to learn how the next-generation high-throughput proteomics empowers genetically-informed assessment of protein causality and the confident identification of actionable drug targets. Adding proteomics to population-scale genetic datasets takes genomics a major step closer to phenotype. This opens new possibilities to explore biological pathways and their interconnections.
Discover the World’s Largest Proteogenomics Study
Proteomics is advancing precision medicine through large-scale initiatives such as the UK Biobank Pharma Proteomics Project (UKB-PPP). This collaboration united 13 of the leading biopharmaceutical companies to generate new proteomic data by accessing samples from individuals in the UK Biobank. The next phase of the project will involve generating proteomic data on more than 5,400 proteins from 600,000 samples using the Olink Explore HT platform. This provides the scientific community with unparalleled data access, enabling breakthrough discoveries that will shape the future of human health and precision medicine.
CoLab Session:
NGS-based Proteomics in Practice: A hands-on Exploration of Population-level Insights.
October 15, 2025 | 10:15 AM – 10:45 AM | Theatre #1
A practical session on NGS-based proteomics: from constructing a biomarker signature to validating it against RNA readouts in metabolic disease. We encourage you to come with questions about QC, analysis approaches, and how to access publicly available datasets to build confidence in using proteomics.
Industry Session:
Advancing Rare Disease Discovery and Precision Medicine with Proteomic-driven Insights.
October 15, 2025 | 12:00 PM – 01:00 PM | Room 204AB
Despite advances in genomics, many individuals with rare diseases remain without answers. Proteomics offers an approach to close this gap by directly capturing molecular signatures of disease in blood.
Applying Olink’s scalable NGS-based proteomic profiling to participants from the 100,000 Genomes Project uncovered novel disease-causing variants and molecular signatures that had been invisible to genetic analysis alone. Notably, proteomic patterns pointed to disease biology in genes not previously linked to the patients’ conditions, revealing entirely new opportunities for clinical insight.
These studies underscore the transformative potential of proteomics to reshape rare disease research, uncover new biological pathways, and innovate population-scale medicine. In doing so, proteomics delivers insights beyond the reach of genomics alone and accelerates our understanding of disease biology.
There’s more to come , so stay tuned for more updates!